Condition: Necrotizing Enterocolitis · Sponsor: Noveome Biotherapeutics, formerly Stemnion
The primary objective of this study is to determine the safety and tolerability of two dose levels (0.5 mL/kg and 1.0 mL/kg) of once daily (QD) via IV route of administration of ST266 in treating patients with Bell's stage IIA or higher medical NEC by incidence of treatment emergent adverse events (TEAEs) and SAEs, with a secondary objective to assess preliminary efficacy of the same two dose levels (0.5 mL/kg and 1.0 mL/kg) of QD via IV route of administration of ST266 in treating patients with Bell's stage IIA or higher medical NEC.
This description comes directly from the study's public registry record.
Karin Potoka, MD · 412-512-1446 · kpotoka@noveome.com
Shawna M Rose, BS · 513-205-1091 · srose@noveome.com
Always discuss trial participation with your own doctor first.
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | Recruiting |
| University of Arkansas for Medical Sciences | Little Rock, Arkansas, United States | Recruiting |
| Yale-New Haven Hospital | New Haven, Connecticut, United States | Recruiting |
| BayCare Health System-St. Joseph's Women's Hospital | Tampa, Florida, United States | Recruiting |
| NorthShore University-Evanston Hospital | Evanston, Illinois, United States | Recruiting |
| Oklahoma Children's Hospital | Oklahoma City, Oklahoma, United States | Recruiting |
| Penn State Health Milton S Hershey Medical Center/Penn State University College of Medicine | Hershey, Pennsylvania, United States | Recruiting |
| University of Pittsburgh Medical Center Magee Womens Hospital | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06315738